2010年9月16日澳洲股市報告包括：Conquest Mining(ASX:CQT)與山東國大黃金股份有限公司簽訂Mt Carlton項目的V2礦生產的金銀銅的承銷合同；Heemskirk Consolidated Limited (ASX:HSK)宣布與Conquest Mining Limited (ASX:CQT)簽訂了一份協議；Imugene Limited (ASX:IMU)今天宣布，已在美國一家豬試驗專業機構成功完成豬繁殖與呼吸綜合症(PRRS)疫苗的第二次試驗；Synthesis Energy Systems Inc. (NASDAQ:SYMX) 和Coalworks Limited (ASX:CWK)今天聯合發表了題為“利用U-GAS(R)和MTG甲醇制汽油技術，以Oaklands煤生產液體燃料”的報告。
Imugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.